circadian clock raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-12 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
== Structure == MIP family channels consist of homotetramers (e.g., GlpF of E. coli; TC #1.A.8.1.1, AqpZ of E. coli; TC #1.A.8.3.1, and MIP or Aqp0 of Bos taurus; TC #1.A.8.8.1). Each subunit spans the membrane six times as putative α-helices. The 6 TMS domains are believed to have arisen from a 3-spanner-encoding genetic element by a tandem, intragenic duplication event. The two halves of the proteins are therefore of opposite orientation in the membrane. A well-conserved region between TMSs 2 and 3 and TMSs 5 and 6 dip into the membrane, each loop forming a half TMS. A common amino acyl motif in these transporters is an asparagine–proline–alanine (NPA) motif. Aquaporins generally have the NPA motif in both halves, the glycerol facilitators generally have an NPA motif in the first haves and a DPA motif in the second halves, and the super-aquaporins have poorly conserved NPA motifs in both halves.
MiniMed Paradigm is a series of insulin pumps manufactured by Medtronic for patients with diabetes mellitus. The pump operates with a single AAA battery and uses a piston-plunger pump to infuse a programmed amount of insulin into the patient through a length of tubing. The Paradigm uses a one-way wireless radio frequency link to receive blood sugar measurements from select glucose meters. The Paradigm RT (Real Time) series adds the ability to receive data from a mated continuous blood-glucose monitor. Although the pump can use these measurements to assist in calculating a dose of insulin, no actual change in insulin delivery occurs without manual user-intervention. In the United States, the device is regulated by a branch of the Food and Drug Administration. Medtronic's successor to the Paradigm, the 670G, was released in 2015. On the same platform, Medtronic released the 780G in 2020 and in the United States in 2023.
Nalorphine (INNTooltip International Nonproprietary Name; also known as N-allylnormorphine; brand names Lethidrone and Nalline) is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence. Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.
====== Medication assisted treatment (MAT): Opioid agonist therapy (OAT) and Opioid substitution therapy (OST) ====== Medication assisted treatment (MAT) is the prescription of legal, prescribed opioids or other drugs, often long-acting, to diminish the use of illegal opioids. Many types of MAT exist, including opioid agonist therapy (OAT) where a safer opioid agonist is employed or opioid substitution therapy (OST) which employs partial opioid agonists. However, MAT, OAT, OST are often used synonymously. Opioid agonist therapy (OAT) involves the use of a full opioid agonist treatment like methadone and is generally taken daily at a clinic. Opioid substitution therapy (OST) involves the use of the partial agonist buprenorphine or a combination of buprenorphine/naloxone (brand name Suboxone). Oral/sublingual formulations of buprenorphine incorporate the opioid antagonist naloxone to prevent people from crushing the tablets and injecting them. Unlike methadone treatment, buprenorphine therapy can be prescribed month-to-month and obtained at a traditional pharmacy rather than a clinic. The driving principle behind OAT/OST is the program's capacity to facilitate a resumption of stability in the person's life, while they experience reduced symptoms of withdrawal symptoms and less intense drug cravings; however, a strong euphoric effect is not experienced as a result of the treatment drug. In some countries, such as Switzerland, Austria, and Slovenia, patients are treated with slow-release morphine when methadone is deemed inappropriate due to the individual's circumstances.
Sources: en.wikipedia.org
=== High Point Media === After Phillips sold his majority interest in EAS, he concentrated on his writing and on promotion of his books through his publishing company, High Point Media, as well as Value Creation, a branch of EAS. Body for Life hit bookstores in 1999, and by 2003 it had sold 3.5 million copies in 24 languages. The book topped the charts in 11 different countries-including the United States, England, Japan, Australia, Greece and Finland. In 2004 USA Today named it among the Top 15 bestselling books of the past decade. In November 2003, Eating for Life: Your Guide to Great Health, Fat Loss and Increased Energy! was released. In the book Phillips offers his plan "to help inspire and guide even more people to improve their health and lift their quality of life to new heights." In February 2006, Phillips announced his "Great American Transformation Experience" (GATE) with a goal to transform America's fitness from world's worst to first within 10 years. On June 21, 2010, Phillips' latest book, Transformation: The Mindset You Need. The Body You Want. The Life You Deserve was released. A companion website, Transformation.com, that walks individuals through the transformation process was also updated. The site features a community dedicated to supporting its members' personal goals. On July 10, 2010, the book made the New York Times Best Seller list.
Competition law aims "to prevent competition from being distorted to the detriment of the public interest, individual undertakings and consumers", especially by limiting big business power. It covers all types of enterprise or "undertaking" regardless of legal form, or "every entity engaged in an economic activity", but not non-profit organisations based on the principle of solidarity, or bodies carrying out a regulatory function. Employees and trade unions are not undertakings, and are outside the scope of competition law, and so are solo self-employed workers, because on long-standing consensus in international law labour is not a commodity, and workers have structurally unequal bargaining power compared to business and employers. A legal professional body setting regulatory standards was held to be outside competition law, and so were the rules of the International Olympic Committee and the International Swimming Federation in prohibiting drugs, because although drugs might increase "competition", the "integrity and objectivity of competitive sport" was more important. EU competition law only regulates activities where trade between member states is affected to an "appreciable" degree, but member states may have higher standards that comply with social objectives. The four most important sets of rules relate to monopolies and enterprises with a dominant position, mergers and takeovers, cartels or collusive practices, and state aid.
Aortic stenosis Congenital heart disease Hypertensive heart disease Hypertrophic cardiomyopathy The common factor amongst all these diseases is that they all cause varying degrees of remodelling (myocardial fibrosis) of the ventricles.
'funded by a pharmaceutical company (Servier) and two of its authors are employees of that company', which may bias the results. The study authors' note: "emotional blunting is reported by nearly half of depressed patients on antidepressants and that it appears to be common to all monoaminergic antidepressants not only SSRIs". Additionally, they note: "The OQuESA scores are highly correlated with the HAD depression score; emotional blunting cannot be described simply as a side-effect of antidepressant, but also as a symptom of depression. More emotional blunting is associated with a poorer quality of remission.
The mine chose to send all ore to the crusher and to concentrate on copper production due to the rising price of copper on the world market. The price of natural untreated Sleeping Beauty turquoise has risen dramatically since the mine's closing. The Kingman Mine as of 2015 still operates alongside a copper mine outside of the city. Other mines include the Blue Bird mine, Castle Dome, and Ithaca Peak, but they are mostly inactive due to the high cost of operations and federal regulations. The Phelps Dodge Lavender Pit mine at Bisbee ceased operations in 1974 and never had a turquoise contractor. All Bisbee turquoise was "lunch pail" mined. It came out of the copper ore mine in miners' lunch pails. Morenci and Turquoise Peak are either inactive or depleted. Nevada is the country's other major producer, with more than 120 mines which have yielded significant quantities of turquoise. Unlike elsewhere in the US, most Nevada mines have been worked primarily for their gem turquoise and very little has been recovered as a byproduct of other mining operations. Nevada turquoise is found as nuggets, fracture fillings and in breccias as the cement filling interstices between fragments. Because of the geology of the Nevada deposits, a majority of the material produced is hard and dense, being of sufficient quality that no treatment or enhancement is required. While nearly every county in the state has yielded some turquoise, the chief producers are in Lander and Esmeralda counties.
Sources: en.wikipedia.org
== Pharmacokinetics and pharmacodynamics == The pharmacokinetics of NACA remain unclear or unstudied. It is an amide derivative of NAC that is rapidly converted to NAC after systemic administration. The bioavailability of NACA is significantly higher than NAC (67% and 15%,). Its mechanism of action involves replenishment of glutathione (GSH), a major antioxidant, and direct neutralization of reactive oxygen species.
Semaglutide is chemically similar to human GLP-1. The first six amino acids of GLP-1 are missing. Substitutions are made at GLP positions 8 and 34 (semaglutide positions 2 and 28), where alanine and lysine are replaced by 2-aminoisobutyric acid and arginine, respectively. The substitution of the alanine prevents chemical breakdown by dipeptidyl peptidase-4. The lysine at GLP position 26 (semaglutide position 20) has a long chain attached, ending with a chain of 18 carbon atoms and a carboxyl group. This increases the drug's binding to blood protein (albumin), which enables longer presence in the blood circulation. Semaglutide's half-life in the blood is about seven days (165–184 hours).
== Principles == Electron-capture dissociation typically involves a multiply protonated molecule M interacting with a free electron to form an odd-electron ion. Liberation of the electric potential energy results in fragmentation of the product ion.
Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies. This includes allergic rhinitis (hay fever) and hives. It is also available in drug combinations such as loratadine/pseudoephedrine, in which it is combined with pseudoephedrine, a nasal decongestant. It is taken orally. Common side effects include sleepiness, dry mouth, and headache. Serious side effects are rare and include allergic reactions, seizures, and liver problems. Use during pregnancy appears to be safe but has not been well studied. It is not recommended in children less than two years old. It is in the second-generation antihistamine family of medications. Loratadine was patented in 1980 and came to market in 1988. It is on the World Health Organization's List of Essential Medicines. Loratadine is available as a generic medication. In the United States, it is available over the counter. In 2023, it was the 105th most commonly prescribed medication in the United States, with more than 6 million prescriptions; and the combination with pseudoephedrine was the 300th most commonly prescribed medication in the United States, with more than 400,000 prescriptions.
==== Mechanism of action ==== Suvorexant is thought to exert its therapeutic effects in the treatment of insomnia by blocking the orexin receptors and thereby inhibiting the effects of the endogenous wakefulness-promoting orexin neuropeptides orexin-A and orexin-B. The orexin neuropeptides are produced exclusively by a relatively small population of 20,000 to 80,000 neurons located in the lateral hypothalamus in the brain. These neurons project widely throughout the brain and mediate excitatory signaling to key centers involved in sleep–wake regulation, including the noradrenergic locus coeruleus, histaminergic tuberomammillary nucleus, serotonergic raphe nucleus, and dopaminergic ventral tegmental area. The orexin system shows circadian rhythmicity in its activity, with high activity during waking and low to no activity during sleep or at night. Orexin system activity during wakefulness is also higher with behavioral activation and with high-intensity emotions. Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations, as well as sleep attacks and fragmented sleep. Narcolepsy with cataplexy, also known as type 1 narcolepsy, is thought to be caused by loss of orexin-producing neurons in the lateral hypothalamus, possibly mediated by autoimmune mechanisms related to environmental triggers in genetically susceptible individuals.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.